Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C19 | P33261 | 1/20 | 0.62 |
| ▸ | EPHX1 | P07099 | 5/20 | 0.48 |
| ▸ | ACP3 | P15309 | 2/20 | 0.47 |
| ▸ | CES2 | O00748 | 1/20 | 0.47 |
| ▸ | PNMT | P11086 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | PTGFR | P43088 | 1/20 | 0.43 |
| ▸ | CPN1 | P15169 | 1/20 | 0.42 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.42 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.42 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.42 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.42 |
| ▸ | PPARG | P37231 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4024222 | 0.85 | CYP2C19 (0.56) | CYP2C19CES2 | |
| SCHEMBL5370750 | 0.85 | CYP2C19 (0.56) | CYP2C19CES2 | |
| SCHEMBL6368432 | 0.82 | CHRM2 (0.54) | EPHX1ACP3CES2PNMTMEN1 | |
| SCHEMBL27501995 | 0.82 | PNMT (0.51) | EPHX1ACP3CES2PNMTMEN1 | |
| SCHEMBL6368425 | 0.82 | CHRM2 (0.54) | EPHX1ACP3CES2PNMTMEN1 | |
| SCHEMBL6368429 | 0.82 | CHRM2 (0.54) | EPHX1ACP3CES2PNMTMEN1 | |
| SCHEMBL4022595 | 0.81 | CYP2C19 (0.68) | CYP2C19EPHX1CES2MEN1KMT2A | |
| SCHEMBL21194004 | 0.81 | PNMT (0.62) | EPHX1ACP3CES2PNMTMEN1 | |
| SCHEMBL3674481 | 0.81 | MEN1 (0.61) | ACP3CES2PNMTMEN1ALDH1A1 | |
| SCHEMBL17085708 | 0.79 | MEN1 (0.51) | MEN1ALDH1A1CYP1A2POLBCYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3116877-A1 | CHEMICAL COMPOUNDS ACTING AS PERK INHIBITORS | Glaxosmithkline Intellectual Property (No. 2) Limited (GB) | 2017-01-18 | — | — | EP | disclosed |
| WO-2015136463-A1 | CHEMICAL COMPOUNDS ACTING AS PERK INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2015-09-17 | — | — | WO | disclosed |
| WO-2015136463-A1 | CHEMICAL COMPOUNDS ACTING AS PERK INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2015-09-17 | — | — | WO | disclosed |
| EP-1497265-B1 | COMPOUNDS HAVING AFFINITY AT 5HT2C RECEPTOR AND USE THEREOF IN THERAPY | GLAXO GROUP LTD (GB) | 2009-02-18 | — | — | EP | disclosed |
| US-20050203079-A1 | Compounds having affinity at 5ht2C receptor and use thereof in therapy | GLAXO GROUP LIMITED | 2005-09-15 | — | — | US | disclosed |
| EP-1497265-A1 | COMPOUNDS HAVING AFFINITY AT 5HT2C RECEPTOR AND USE THEREOF IN THERAPY | GLAXO GROUP LIMITED (GB) | 2005-01-19 | — | — | EP | disclosed |
| WO-2003089409-A1 | COMPOUNDS HAVING AFFINITY AT 5HT2C RECEPTOR AND USE THEREOF IN THERAPY | GLAXO GROUP LIMITED (GB) | 2003-10-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050203079-A1 | Compounds having affinity at 5ht2C receptor and use thereof in therapy | HTR7, HTR2C, HTR3C | CYP2C19 245/4885EPHX1 1554/4885ACP3 4651/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.